Cardio-Respiratory synchronized bSSFP MRI for high throughput in vivo lung tumour quantification

Ana L. Gomes, Paul Kinchesh, Stuart Gilchrist, Philip D. Allen, Luiza Madia Lourenço, Anderson J. Ryan, Sean C. Smart

Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

* Current address: Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
* ana.gomes@crick.ac.uk

Abstract

The identification and measurement of tumours is a key requirement in the study of tumour development in mouse models of human cancer. Disease burden in autochthonous tumours, such as those arising in the lung, can be seen with non-invasive imaging, but cannot be accurately measured using standard tools such as callipers. Lung imaging is further complicated in the mouse due to instabilities arising from the rapid but cyclic cardio-respiratory motions, and the desire to use free-breathing animals. Female A/JOlAhsd mice were either injected (i.p.) with PBS 0.1ml/10g body weight (n = 6), or 10% urethane/PBS 0.1ml/10g body weight (n = 12) to induce autochthonous lung tumours. Cardio-respiratory synchronised bSSFP MRI, at 200 μm isotropic resolution was performed at 8, 13 and 18 weeks post induction. Images from the same mouse at different time points were aligned using threshold-based segmented masks of the lungs (ITK-SNAP and MATLAB) and tumour volumes were determined via threshold-based segmentation (ITK-SNAP). Scan times were routinely below 10 minutes and tumours were readily identifiable. Image registration allowed serial measurement of tumour volumes as small as 0.056 mm³. Repetitive imaging did not lead to mouse welfare issues. We have developed a motion desensitised scan that enables high sensitivity MRI to be performed with high throughput capability of greater than 4 mice/hour. Image segmentation and registration allows serial measurement of individual, small tumours. This allows fast and highly efficient volumetric lung tumour monitoring in cohorts of 30 mice per imaging time point. As a result, adaptive trial study designs can be achieved, optimizing experimental and welfare outcomes.

Introduction

Lung cancer is currently the major cause of cancer related deaths worldwide. Despite treatment advances in other types of cancer, current chemotherapy strategies have proven to be only marginally effective with only 10% of UK lung cancer patients surviving 5 years after...
diagnosis [1]. This is mainly due to patients presenting with late stage disease. Therefore, both better therapies and early diagnostic tools are needed to improve the prognosis of lung cancer patients.

Murine models of lung cancer mimicking different aspects of the human disease are already available [2], but disease progression monitoring and scoring of real-time response to therapy have proven to be more challenging. Preclinical in vivo imaging of the lung is usually done using either x-ray Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI). MRI provides good spatial resolution and detection of soft tissue pathology whilst avoiding the delivery of ionising radiation as required for CT. Previous reports have suggested that lung tumours are hard to detect on CT in mice, but MRI provides good tumour to lung parenchyma contrast [3]. The requirement for CR-synchronization has also been demonstrated but in these scans there were significant periods in which data were not being acquired, compromising image capture efficiency. Regardless of the imaging speed, good correlations of tumour size by MRI with ex vivo tumour mass or diameter were given thereby validating the use of MRI in tumour volumetry for a range of scans mode, including echo-planar, FLASH, and spin-echo MRI [3–5].

MRI of the lung is challenging. The low proton density and the magnetic susceptibility induced signal losses [6], resulting from the large amount of air-tissue interface as required for gas exchange, often render the lung parenchyma invisible. However, solid tumours have relatively high proton density and do not experience these magnetic susceptibility-induced signal losses to the same extent as parenchyma. Furthermore, the effects of susceptibility can be minimised through the use of spin echo techniques of which the bSSFP scan we describe is one [7]. Another major challenge for these tumours is that the lung moves under the influence of both cardiac and respiratory motions; it is, after all functionally positioned in-between the right ventricle and the left atrium of the heart. Several 1H-based imaging methods have been developed such as hyperoxia enhancement [8, 9], inversion recovery imaging [10–12], and ultra-short [9, 13] or zero echo time (TE) [14]. Other non 1H-based methods have also been developed such as hyperpolarized helium-3 (3He) or xenon-129 (129Xe) imaging of the lung parenchyma [15–17], but these methods are expensive and some adverse effects with 129Xe, though transient, have been reported for some patients [18]. Further complications in lung imaging are derived from the respiratory and cardiac motions, and these result in unacceptable image corruptions which may hinder or prevent the detection of pathology. The detection of small tumours in the mouse lung requires fast and high-resolution scans that are desensitised to these cardiac and respiratory motions. For the reduction of motion-derived image artefacts, retrospective gating methods have been used [19, 20] but these are necessarily slow due to the repeated acquisition of equivalent imaging data lines over multiple physiological cycles. We have previously shown that prospective gating control can be used to accelerate the production of high-resolution bSSFP (balanced Steady-State Free Precession) images of the mouse lung in vivo [21], and we now show that the technique is sensitive to the detection of small lung tumours, enabling in vivo quantification of tumour growth curves. By optimizing the gating control system, we have been able to develop a suitable Cardio-Respiratory (CR)-synchronized bSSFP scan operating at an isotropic resolution of ca. 200 μm, with an average turnaround time of <15 mins per mouse.

We demonstrate the new CR-synchronized bSSFP scan in urethane-induced model of lung cancer in the mouse. We chose this model because distinct tumours arise stochastically throughout the lung and then grow relatively slowly over a period of months. As it is a stochastic model, it is unknown when and where tumours will first be detectable. Also, as it is a slow growing model, we can test if the developed CR-synchronized bSSFP scan can detect small...
changes in tumour growth in vivo. The latter is likely to be important when monitoring tumour response to therapy.

**Methods**

**Animal model**

Experiment was conducted in accordance with the Animals Scientific Procedures Act of 1986 (UK) (Project License Number 30/3395 issued by the Home Office). The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Oxford. Mice were housed (n = 6 per cage) in individual ventilated cages in a separate room with 12h dark and light cycle maintained at 22°C in 50% humidity. Mice were given certified rodent diet, filtered water ad libitum, autoclaved bedding material and cage enrichment. No animal was euthanized on welfare grounds.

Urethane (10% urethane/PBS, 0.1mL/10g body weight, n = 12) or saline alone (0.1mL/10g body weight, n = 6) was injected i.p. in 6–8 week old A/JOlaHsd female mice weighing 20.2 ± 1.8 g (Envigo UK, #049). Urethane treated mice will henceforth be referred to as urethane mice and saline treated mice will henceforth be referred to as controls. This strain was chosen because it is described as particularly sensitive to urethane-induced lung tumours [22–24].

Six mice were killed by schedule 1 method at 24 weeks, and lungs were collected and placed in 10% buffered formalin at 4°C, for 48 h. Lungs were then transferred to 70% ethanol solution and visually inspected and surface tumours counted.

**MR imaging**

MR imaging was performed at weeks 8, 13, and 18 after tumour induction. All mice were placed in a head-first supine position for imaging. Anaesthesia was induced and maintained using isoflurane (1–4%) in room air supplemented with oxygen (80%/20%). Temperature was monitored with an optical rectal probe (OTP-M, Opsens Inc, Quebec, Canada) connected via a fibre-optic extension to an AccuSense Signal Conditioner (ACS-P4-N-62SC, Opsens Inc) that provided feedback to a twisted pair resistive heating system specifically developed for MR compatible homoeothermic maintenance [25]. Respiration was monitored for prospective gating using a pressure balloon positioned against the animal’s chest. ECG was detected using subcutaneously implanted needles positioned in the lower abdomen. Throughout imaging, mice were maintained at 37°C, respiration rate was monitored and maintained at 40–60 breaths/mins with approximately 60–70% of the respiration cycle available for imaging, and all efforts were made to minimize suffering.

**MR methods**

MRI was performed at 7.0 T (Varian VNMRS), using a 30 mm long 25 mm ID quadrature birdcage coil (Rapid Biomedical). CR-synchronised bSSFP scans were performed volumetrically with automatic and immediate reacquisition of data corrupted by respiration motion [21] and operated such that the scan automatically adapted to any instantaneous changes in respiration rate. Scan parameters were TR 2.8 ms, TE 1.4 ms, RF hard pulse 16 μs, FA 30°, FOV 51.2×25.6×25.6 mm³, matrix 256×128×128, and N = 32 k-lines per R-wave to give a single 3D data set with 200 μm isotropic resolution in less than 2.5 minutes. A pulse sequence schematic is given in Fig 1. bSSFP banding artefacts were robustly removed with combination of four phase-cycled images acquired in less than 10 minutes in total using an elliptical signal model.
All acquired scans are available at the Oxford University Research Archive Depositary (DOI: 10.5287/bodleiain:xqabzAD9e).

**Image analysis**

**Volume segmentations and image registrations.** 3D masks of both tumours and lungs were created by a threshold-based, seed point driven, semi-automatic segmentation using...
ITK-SNAP [27]. Lung and tumour volume were measured from these masks. Images from the same animal at different time points were registered using an iterative closest point algorithm to find the best alignment between the corresponding lung masks [28]. Quality control of the registrations was done by quantifying the Dice Coefficients between the registered images [29]. Lung masks from the acquired scans plus the registered images/scans are available at the Oxford University Research Archive Depositary (DOI: 10.5287/bodleia:in:xqabzAD9e).

Statistical analysis

All statistical analysis was done using Excel (Office 2013). Results are shown as average and standard deviation of population. Statistical significance was assessed using two-tailed, unequal variance Student’s t-Test. P-values of less than 0.05 were considered significant.

Results and discussion

bSSFP MR imaging allows high throughput screening

MR bSSFP scan times, for an isotropic resolution of 200 μm, were all below 10 minutes per mouse. Including shimming, frequency offset and RF pulse calibrations the turnaround time...
per mouse was under 15 minutes, enabling a throughput exceeding 4 mice per hour. Such high throughput means that it would be feasible to do studies for which in vivo imaging of larger sample sizes is needed (>30 mice scanned per normal working day).

**bSSFP MR imaging allows rapid tumour burden quantification**

Average lung volume for the urethane mice significantly increased from week 8 (388.55 mm$^3$ ± 48.01) to week 18 (444.31 mm$^3$ ± 45.34; $p = 0.01$). In control mice this difference was not significant (week 8: 373.50 mm$^3$ ± 28.08; week 18: 434.18 mm$^3$ ± 111.31; $p = 0.284$) (Fig 2A). The non-significance in the volume of the growing lungs in the control group is most likely attributed to the greater inter-mouse lung volume variation and the smaller number of animals in this groups, when compared to the urethane-treated group. Of note, there is partial lung volume loss in the superior and/or middle right lobes in 14 mice at week 8 (14/18, 77.8%), 11 mice at week 13 (11/18, 61.1%), and 6 mice at week 18 (6/18; 33.3%) post treatment (i.p. urethane or saline) (Fig 2B, orange dotted line on the MR scans). This partial lung volume loss was present in both treatment groups, and therefore it can be ruled out that it is part of the underlying urethane-induced pathology. Lung fibrosis can also be excluded, as the signal detected in the superior and/or middle right lobes disappears at later time points in all but two mice (Ctr4 and M5). The most likely scenario is anaesthesia induced atelectasis [30].

No tumours were unequivocally detected at week 8 post induction. The average number of tumours per urethane mouse was 5.3 ± 1.0 and 13.3 ± 2.3 at weeks 13 and 18, respectively (Fig 2C). These values are in line with previous studies published for this model [22, 31]. Also, total tumour volume was 1.2 ± 0.5 mm$^3$ and 5.3 ± 1.8 mm$^3$ at weeks 13 and 18, respectively (Fig 2C). All tumours measured increased in size from week 13 to week 18. No tumours were detected in any of the control mice. Quantification of individual mice tumour burden (defined

---

**Table 1. Registration quality control check per mouse as Dice coefficients, between week 13 and week 18 scans.** Numbers in bold represent successful registrations which have Dice coefficients above the pre-set registration quality control threshold.

| Mouse id | Mask volume (mm$^3$) | Dice coefficient |
|----------|----------------------|------------------|
|          | week 13   | week 18    |                      |
| Ctr1     | 325.2     | 387.0      | 0.786               |
| Ctr2     | 398.5     | 558.2      | 0.740               |
| Ctr3     | 436.1     | 457.3      | 0.830               |
| Ctr4     | 360.1     | 341.0      | 0.781               |
| Ctr5     | 477.8     | 584.9      | 0.785               |
| Ctr6     | 304.5     | 276.7      | 0.500               |
| M1       | 508.0     | 488.3      | 0.903               |
| M2       | 391.5     | 544.6      | 0.778               |
| M3       | 468.8     | 416.9      | 0.867               |
| M4       | 353.0     | 423.5      | 0.784               |
| M5       | 336.4     | 353.1      | 0.836               |
| M6       | 420.8     | 436.7      | 0.819               |
| M7       | 433.8     | 452.1      | 0.806               |
| M8       | 406.1     | 421.6      | 0.809               |
| M9       | 353.2     | 454.7      | 0.782               |
| M10      | 424.7     | 451.7      | 0.737               |
| M11      | 250.0     | 409.8      | 0.560               |
| M12      | 456.2     | 478.7      | 0.660               |

[https://doi.org/10.1371/journal.pone.0212172.t001](https://doi.org/10.1371/journal.pone.0212172.t001)
as the total volume of tumours divided by the total lung volume) showed that tumours grew at different rates, in spite being in the same mouse lung (Fig 2D). For 6 urethane mice, lungs were further inspected visually post-mortem, and number of lung surface tumours per mouse were quantified by eye. Although the mean number of tumours per mouse lung was higher when quantified by visual inspection of the excised lungs (17.8 ± 2.6) at 24 weeks than by our MRI method (14.8 ± 2.1) at 18 weeks, there was no significant difference between the results obtained by both methods ($\rho = 0.122$; Fig 2E). Imaging was not performed at week 24 due to operational issues within the imaging facility, as a result of which we could not perform a systematic comparison of tumour number by MR with post-mortem examination at this time. It is quite conceivable that the mean number of tumours measured visually at 24 weeks is greater than the number of tumour measured by MRI at 18 weeks. This could be attributed to tumours at 18 weeks being below the limit of detection for MRI, where this limit would be primarily defined by the imaging resolution, the cell density, and the cell water content. Furthermore, whilst previous reports have indicated a good correlation of tumour volume by MRI and ex vivo mass, these have not specified any limit of detection [32, 33].

Fig 3. A) Cross-section of registered lung mask for week 13 (red) and 18 (black) showing registration quality control check as Dice coefficients. B) Example of registered 3D segmentations illustrating good (M1, left-side) and bad (M12, right-side) registrations. Week 13 mask is shown in red and week 18 mask is shown in light blue.

https://doi.org/10.1371/journal.pone.0212172.g003
Image registration allows individual in vivo tumour growth curves quantification

For each mouse, images measured at week 13 were registered to those measured at week 18 using a rigid body registration that was chosen as it retained volumetric detail. Images from week 8 were not registered as they did not feature tumours and as growth and/or reshaping of the lungs prevented use of the rigid body registration used. The resulting alignment improved visual identification of individual tumours and their first appearance and growth, as matched slices could be displayed simultaneously, but it did not influence measurement of tumour volumes.

The quality control of registration was assessed by quantifying Dice coefficients, as summarised in Table 1.

A middle slice of the registered lung masks per mouse can be seen in Fig 3A. A Dice coefficient above 0.800 was considered good and individual tumours in 6/12 mice were easily mapped and quantified semi-automatically through use of a shared seed point for the segmentation. Individual tumour mapping and quantification was also possible for mice with Dice coefficient of 0.778 or above (in three further mice M2, M4, and M9, Fig 3A), but this required manual positioning of the seed points for images acquired at the two time points. For the other three mice, the automatic segmentation technique failed due to atelectasis, but manual volumetry quantification was still possible. As the unambiguous identification of individual tumours from one timepoint to the other was not possible for these mice, no further attempt

### Table 2. Volumes (mm$^3$) of individual tumours (T1-T18), per mouse (M1-M9), per time point (w13-w18).

| T1      | M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 |
|---------|----|----|----|----|----|----|----|----|----|
| T1      | 0.080 | 0.136 | 0.272 | 0.168 | 1.072 | 0.192 | 0.488 | 0.288 | 0.680 | 0.184 | 0.672 |
| T2      | 0.072 | 0.176 | 0.248 | 0.080 | 1.496 | 0.104 | 0.176 | 0.152 | 0.296 | 0.144 | 0.248 |
| T3      | 0.160 | 0.184 | 1.184 | 0.184 | 0.528 | 0.056 | 0.176 | 0.160 | 0.408 | 0.056 | 0.248 |
| T4      | 0.168 | 0.752 | 0.272 | 0.392 | 0.128 | 0.288 | 0.056 | 0.120 | 0.056 | 0.176 | 0.616 |
| T5      | 0.080 | 0.336 | 0.192 | 0.288 | -   | 0.368 | -   | 0.152 | 0.368 | 1.416 | 0.144 |
| T6      | 0.096 | 0.192 | 0.760 | 0.184 | -   | 0.184 | 1.200 | 0.128 | 0.248 | 0.392 | 0.792 |
| T7      | 0.152 | 0.152 | 0.480 | 0.200 | 0.160 | 0.208 | -   | 0.072 | -   | 0.056 | 0.096 |
| T8      | 0.240 | 0.328 | 0.360 | 0.304 | -   | 0.056 | -   | 0.256 | -   | 0.176 | 0.192 |
| T9      | 0.480 | 0.256 | 0.416 | 0.208 | 0.672 | -   | 0.248 | -   | 0.072 | -   | 0.152 |
| T10     | 0.112 | 0.232 | 0.088 | -   | 0.104 | 0.232 | -   | 0.072 | -   | 0.104 | 0.248 |
| T11     | 0.104 | 0.352 | 0.208 | -   | 0.184 | -   | 0.128 | 0.248 | 0.392 | 0.729 | 0.382 |
| T12     | 0.184 | 0.304 | 0.608 | -   | 0.072 | -   | 0.152 | -   | 0.144 | 0.056 |
| T13     | 0.128 | 0.104 | 0.072 | -   | 0.072 | 0.104 | 0.232 | -   | 0.080 | 0.344 |
| T14     | 0.304 | 0.200 | -   | 0.152 | 0.472 | 0.712 |
| T15     | 0.320 | 0.360 | 0.152 | 0.128 | 0.152 |
| TTV     | 0.560 | 4.848 | 0.560 | 7.336 | 0.616 | 2.624 | 1.184 | 4.784 | 1.328 | 4.816 | 2.232 |
| AVT     | 0.112 | 0.269 | 0.192 | 0.312 | 0.140 | 0.524 | 0.123 | 0.262 | 0.197 | 0.532 | 0.190 |
| SDV     | 0.043 | 0.160 | 0.044 | 0.232 | 0.040 | 0.371 | 0.065 | 0.170 | 0.102 | 0.449 | 0.179 |

w13: week 13; w18: week 18; TTV: total tumour volume; AVT: average volume per tumour; SDV: standard deviation of population

https://doi.org/10.1371/journal.pone.0212172.t002
was made to track the growth of these individually. Further refinements to the analysis technique are in development in order to address this issue.

In summary, quantification of individual tumour growth was possible in 9/12 mice, even with tumour volumes estimated to be 0.056 mm$^3$ (Table 2). Additional 3D examples of good (M1) and bad (M12) registrations are given in Fig 3B. In all mice, some tumours were detected already at week 13 while other tumours were only visible at week 18 (Fig 4A and 4B). For the tumours already detected at week 13, individual growth rates were different from tumour to tumour, even within the same mouse lung (Fig 4C, Table 2), highlighting the importance of individual tumour quantification and follow-up.

**Conclusion**

We have developed a rapid CR-synchronized MR scan that allows for high throughput in vivo imaging of lung tumour growth, with less than 15 min turnaround time per mouse. When coupled with the described method for semi-automated registration and quantification, individual lung tumours can be followed. This tracking option is the first step to potentially achieve bigger studies in areas such as tumour preferential location and distribution in the lung and in vivo individual tumour growth kinetics in response to different treatments, including chemo and radiotherapy, among others. Such potential for high throughput provides opportunities...
that include the use of larger sample sizes, more sample groups, more repeated imaging, improved access to limited-availability scanners, and the ability to operate the adaptive trial study designs, optimizing experimental and welfare outcomes.

Supporting information
S1 Appendix. The ARRIVE Guidelines Checklist for this manuscript. (DOCX)

Author Contributions
Conceptualization: Ana L. Gomes, Paul Kinchesh, Sean C. Smart.
Data curation: Ana L. Gomes, Philip D. Allen.
Formal analysis: Ana L. Gomes, Philip D. Allen.
Funding acquisition: Anderson J. Ryan, Sean C. Smart.
Investigation: Ana L. Gomes, Paul Kinchesh, Philip D. Allen, Anderson J. Ryan, Sean C. Smart.
Methodology: Paul Kinchesh, Stuart Gilchrist, Philip D. Allen, Luiza Madia Lourenço, Sean C. Smart.
Project administration: Ana L. Gomes, Sean C. Smart.
Resources: Ana L. Gomes, Luiza Madia Lourenço, Anderson J. Ryan, Sean C. Smart.
Software: Paul Kinchesh, Stuart Gilchrist, Philip D. Allen.
Supervision: Paul Kinchesh, Sean C. Smart.
Validation: Stuart Gilchrist, Sean C. Smart.
Visualization: Ana L. Gomes, Philip D. Allen.
Writing – original draft: Ana L. Gomes.
Writing – review & editing: Ana L. Gomes, Paul Kinchesh, Stuart Gilchrist, Philip D. Allen, Luiza Madia Lourenço, Sean C. Smart.

References
1. Cancer Research UK. Cancer statistics by type. 2014. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer. Cited December 2017.
2. Kellar A, Egan C, Morris D. Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. Biomed Res Int. 2015; 2015:621324. Epub 2015/06/13. https://doi.org/10.1155/2015/621324 PMID: 26064932; PubMed Central PMCID: PMCPMC4433653.
3. Bankson JA, Ji L, Ravoori M, Han L, Kundra V. Echo-planar imaging for MRI evaluation of intrathoracic tumors in murine models of lung cancer. J Magn Reson Imaging. 2008; 27(1):57–62. Epub 2007/12/07. https://doi.org/10.1002/jmri.21221 PMID: 18058933.
4. Krupnick AS, Tidwell VK, Engelbach JA, Alli VV, Nehorai A, You M, et al. Quantitative monitoring of mouse lung tumors by magnetic resonance imaging. Nat Protoc. 2012; 7(1):128–42. Epub 2012/01/10. https://doi.org/10.1038/nprot.2011.424 PMID: 22222788; PubMed Central PMCID: PMCPMC3670466.
5. Olson JD, Walb MC, Moore JE, Attia A, Sawyer HL, McBride JE, et al. A gated-7T MRI technique for tracking lung tumor development and progression in mice after exposure to low doses of ionizing radiation. Radiat Res. 2012; 178(4):321–7. Epub 2012/09/07. PMID: 22950352; PubMed Central PMCID: PMCPMC3478889.
6. Beckmann N, Tigani B, Mazzoni L, Fozard JR. MRI of lung parenchyma in rats and mice using a gradient-echo sequence. NMR in Biomedicine. 2001: 14:297–306. PMID: 11477650
7. Scheffler K, Hennig J. Is TrueFISP a gradient-echo or a spin-echo sequence? Magn Reson Med. 2003; 49(2):395–7. Epub 2003/01/24. https://doi.org/10.1002/mrm.10351 PMID: 12541263.

8. Hemberger KR, Jakob PM, Breuer FA. Multiparametric oxygen-enhanced functional lung imaging in 3D. MAGMA. 2015; 28(3):217–26. Epub 2014/10/10. https://doi.org/10.1007/s10334-014-0462-3 PMID: 25297566.

9. Togao O, Ohno Y, Dimitrov I, Hsia CC, Takahashi M. Ventilation/perfusion imaging of the lung using ultra-short echo time (UTE) MRI in an animal model of pulmonary embolism. J Magn Reson Imaging. 2011; 34(3):539–46. Epub 2011/07/16. https://doi.org/10.1002/jmri.22645 PubMed: 21761465; PubMed Central PMCID: PMCPMC4735664.

10. Jakob PM, Hillenbrand CM, Wang T, Schultz G, Hahn D, Haase A. Rapid quantitative lung T1 mapping. J Magn Reson Imaging. 2001; 14(6):795–9. Epub 1999/05/20. PMID: 10332866.

11. Mai VM, Knight-Scott J, Berr SS. Improved visualization of the human lung in 1H MRI using multiple inversion recovery for simultaneous suppression of signal contributions from fat and muscle. Magn Reson Med. 1999; 41(5):866–70. Epub 1999/05/20. PMID: 10332866.

12. Zurek M, Johansson E, Rissee F, Alamidi D, Olsson LE, Hockings PD. Accurate T1 mapping for oxygen-enhanced MRI in the mouse lung using a segmented inversion-recovery ultrashort echo-time sequence. Magn Reson Med. 2014; 71(6):2180–5. Epub 2013/07/24. https://doi.org/10.1002/mrm.24876 PMID: 23878094.

13. Fain SB, Korosec FR, Holmes JH, O’Halloran R, Sorkness RL, Grist TM. Functional lung imaging using hyperpolarized gas MRI. J Magn Reson Imaging. 2007; 25(5):910–23. Epub 2007/04/06. https://doi.org/10.1002/jmri.20876 PMID: 17410561.

14. Wild JM, Ajraoui S, Deppe MH, Parnell SR, Marshall H, Parra-Robles J, et al. Synchronous acquisition of hyperpolarised 3He and 1H MR images of the lungs—maximising mutual anatomical and functional information. NMR Biomed. 2011; 24(2):130–4. Epub 2010/09/08. https://doi.org/10.1002/nbm.1565 PMID: 20821726.

15. Wang W, Nguyen NM, Yablonskiy DA, Sukstanskii AL, Osmanagic E, Atkinson JJ, et al. Imaging lung microstructure in mice with hyperpolarized 3He diffusion MRI. Magn Reson Med. 2011; 65(3):620–6. Epub 2011/02/22. https://doi.org/10.1002/mrm.22737 PMID: 21337400; PubMed Central PMCID: PMCPMC3526681.

16. Driehuys B, Martinez-Jimenez S, Cleveland ZI, Metz GM, Beaver DM, Nault JC, et al. Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients. Radiology. 2012; 262(1):279–89. Epub 2011/11/08. https://doi.org/10.1148/radiol.11110217 PMID: 22056683; PubMed Central PMCID: PMCPMC344666.

17. Bishop J, Feintuch A, Bock NA, Nieman B, Dazai J, Davidson L, et al. Retrospective gating for mouse cardiac MRI. Magn Reson Med. 2006; 55(3):472–7. Epub 2006/02/02. https://doi.org/10.1002/mrm.20794 PMID: 16450339.

18. Tibletti M, Bianchi A, Kjorstad A, Wundrak S, Stiller D, Rasche V. Respiratory self-gated 3D UTE for lung imaging in small animal MRI. Magn Reson Med. 2017; 78(2):739–45. Epub 2016/09/25. https://doi.org/10.1002/mrm.26463 PMID: 27663453.

19. Kinchesh P, Gilchrist S, Gomes AL, Kersemans V, Beech J, Allen PD, Smart S. Accelerated Imaging of the Mouse Body Using K-Space Segmentation, Cardio-Respiratory Synchronisation and Short, Constant TR: Application to B-SSFP. 24th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2016; Singapore.

20. Festing MF, Yang A, Malkinson AM. At least four genes and sex are associated with susceptibility to urethane-induced pulmonary adenomas in mice. Genet Res. 1994; 64(2):99–106. Epub 1994/10/01. PMID: 7813906.

21. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology. 1989; 54(3):241–71. Epub 1989/03/01. PMID: 2650016.

22. Allen JW, Stoner GD, Pereira MA, Backer LC, Sharief Y, Hatch GG, et al. Tumorigenesis and genotoxicity of ethyl carbamate and vinyl carbamate in rodent cells. Cancer Res. 1986; 46(10):4911–5. Epub 1986/10/01. PMID: 3756853.

23. Kersemans V, Gilchrist S, Allen PD, Beech JS, Kinchesh P, Vojnovic B, et al. A resistive heating system for homeothermic maintenance in small animals. Magn Reson Imaging. 2015; 33(6):847–51. Epub 2015/06/09. https://doi.org/10.1016/j.mri.2015.03.020 PMID: 26012172.
2015/04/12. https://doi.org/10.1016/j.mri.2015.03.011 PMID: 25863135; PubMed Central PMCID: PMCPMC4462590.

26. Xiang QS, Hoff MN. Banding artifact removal for bSSFP imaging with an elliptical signal model. Magn Reson Med. 2014; 71(3):927–33. Epub 2014/01/18. https://doi.org/10.1002/mrm.25098 PMID: 24436006.

27. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31(3):1116–28. Epub 2006/03/21. https://doi.org/10.1016/j.neuroimage.2006.01.015 PMID: 16545965.

28. Kroon D-J. Segmentation of the mandibular canal on cone-beam CT data: University of Twente; 2011.

29. Zou KH, Warfield SK, Bharatha A, Tempany CM, Kaus MR, Haker SJ, et al. Statistical validation of image segmentation quality based on a spatial overlap index. Acad Radiol. 2004; 11(2):178–89. Epub 2004/02/21. https://doi.org/10.1016/S1076-6332(03)00671-8 PMID: 14974593; PubMed Central PMCID: PMCPMC1415224.

30. Wilding LA, Hampel JA, Khoury BM, Kang S, Machado-Aranda D, Raghavendra K, et al. Benefits of 21\% Oxygen Compared with 100\% Oxygen for Delivery of Isoflurane to Mice (Mus musculus) and Rats (Rattus norvegicus). J Am Assoc Lab Anim Sci. 2017; 56(2):148–54. Epub 2017/03/21. PMID: 28315643; PubMed Central PMCID: PMCPMC5361039.

31. Hori Y, Takasuka N, Mutoh M, Kitahashi T, Kojima S, Imaida K, et al. Periodic analysis of urethane-induced pulmonary tumors in living A/J mice by respiration-gated X-ray microcomputed tomography. Cancer Sci. 2008; 99(9):1774–7. Epub 2008/07/12. https://doi.org/10.1111/j.1349-7006.2008.00889.x PMID: 18616525.

32. Wang F, Akashi K, Murakami Y, Inoue Y, Furuta T, Yamada H, et al. Detection of lung tumors in mice using a 1-tesla compact magnetic resonance imaging system. PLoS One. 2014; 9(4):e94945. Epub 2014/04/20. https://doi.org/10.1371/journal.pone.0094945 PMID: 24743153; PubMed Central PMCID: PMCPMC3990561.

33. Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther. 2007; 6(11):1717–25. Epub 2007/11/08. PMID: 17986851.